SNES SenesTech, Inc. Insider Trading

10% owner Capital Management Glenbrook bought 35,000 shares of SNES at $1.51 on 2026-06-30; stock down 76.1% from 52-week high.

Capital Management Glenbrook purchased 35,000 shares at $1.51 on 2026-06-30, bringing total holdings to 1,022,824 shares, in a company trading at $1.49—down 76.1% from its 52-week high of $6.24. This represents a continuation of accumulation activity: the insider executed five separate buy transactions at SNES within a six-day window (2026-06-22 through 2026-06-30). The company is unprofitable, posting a net income of $-2,063,000.00 in its most recent reporting period against revenue of $493,000.00, though annual revenue growth reached +19.6%. The insider's cross-ticker track record shows 20 prior buys averaging -8.2% return over 30 days and -18.7% over 90 days, with a 0.00% win rate at the 90-day mark, suggesting this buying pattern has not historically preceded price recovery.

Capital Management Glenbrook bought 25,416 shares across 4 transactions totaling $39,102.14 (blended avg $1.54) at SNES

Capital Management Glenbrook, a 10% owner, executed 4 separate purchases totaling 25,416 shares for $39,102.14 between June 24–29, 2026, increasing holdings by 2.6% to 987.8K shares. The blended average price of $1.54 sits above the current price of $1.49, and the stock is down 76.1% from its 52-week high of $6.24. The company remains unprofitable (net income $-2.1M in the latest reporting period) while reporting $493.0K in quarterly revenue and positive annual growth of 19.6%. Prior trades by this insider at SNES show limited positive outcome evidence: a 30-day return of +2.0% on an earlier May 18 buy, and 0.0% on a May 15 buy, with most recent purchases not yet measurable. Across all tickers, the insider's 20 prior buys posted an average 90-day return of -16.4% with a 7.69% win rate, suggesting a modest track record for capturing gains.

10% owner Capital Management Glenbrook bought 8,264 shares across 2 trades for $13,563.27 at SNES, expanding stake 0.9%.

Capital Management Glenbrook, a 10% shareholder, executed 2 separate purchases totaling 8,264 shares for $13,563.27 on 2026-06-17 and 2026-06-22 at an average price of $1.64. The current stock price of $1.71 sits -72.6% from its 52-week high of $6.24 and has declined 5.5% over the past 30 days, suggesting the company faces sustained headwinds. The underlying business reports revenue of $493,000.00 for the latest quarter with a net loss of $2,063,000.00 and has been unprofitable over its most recent full fiscal year, raising questions about the company's financial stability. The insider's cross-ticker track record shows 20 prior buys with a 7.69% win rate at the 90-day horizon and an average 90-day return of -16.4%, while same-ticker history at SNES shows 5 prior buys in the preceding weeks with mixed near-term results (two measurable: +2.0% and +0.0% at 30 days), offering limited insight into whether this accumulation pattern reflects conviction or liquidity management in a distressed situation.

10% owner Capital Management Glenbrook buys 28,389 shares at $1.60 avg (3 transactions, $45.5K) as stock down -74.2% from 52-week high

Capital Management Glenbrook, a 10% owner of SenesTech, executed 3 separate purchases totaling 28,389 shares for $45,535.63 over a 4-day period at prices ranging from $1.57 to $1.65, increasing holdings by 3.1%. The timing coincides with significant downward pressure: the stock is -74.2% from its 52-week high of $6.24 and down -6.9% over the prior 30 days. However, the insider's cross-ticker track record shows modest execution skill with an 11.76% win rate and -14.9% average 90-day return on prior buys, and at this specific ticker, only 1 of 5 prior buy trades achieved positive 90-day returns. The company posted revenue of $493,000.00 in the latest quarter with a net loss of $-2,063,000.00, indicating substantial unprofitability despite +19.6% annual revenue growth. The purchases occur within a context of persistent losses and weak near-term price momentum, making this a routine insider accumulation with limited supporting evidence of well-timed market entry.

Capital Management Glenbrook (10% owner) purchases 32,120 shares at blended avg $1.67; stock -74.5% from 52-wk high, -32.6% over 90 days.

Capital Management Glenbrook executed 3 separate purchases totaling 32,120 shares for $53,486.08 between May 14–18, 2026, increasing holdings by 3.6% to 925,755 shares at prices ranging from $1.59 to $1.72. The timing occurs amid significant price pressure: the stock is down -32.6% over the past 90 days and -74.5% from its 52-week high of $6.24, while the company reports quarterly revenue of $493,000.00 and is unprofitable ($-2,063,000.00 net loss). Reviewing the insider's prior 5 trades at SNES, only 1 of 5 buys produced a positive 90-day return, and the most recent purchase on 2026-04-28 (+10.3% at 90 days) is the sole instance of well-timed entry at this ticker. The broader cross-ticker track record shows median underperformance (90-day win rate 14.29%), suggesting the insider's prior buy decisions have struggled to anticipate positive price movements. The severity of the stock's recent decline and the weak historical accuracy of this insider's timing at SNES warrant investor scrutiny of the company's operational and financial trajectory.

10% owner Glenbrook Capital purchases 3,000 shares of struggling biotech as stock hits 52-week lows.

Glenbrook Capital Management, a significant institutional holder with over 10% ownership, purchased 3,000 shares near the stock's recent bottom, suggesting deliberate portfolio averaging rather than strategic conviction. The company is pre-revenue in practical terms—annual revenue trails operating losses by more than tenfold—and the stock trades substantially below its highs from earlier in the year. While Glenbrook's purchase at depressed valuation could signal a belief that SenesTech's biotech prospects are underpriced, institutional purchases at distressed prices are routine portfolio management moves and do not carry the weight of insider conviction from executives with operational knowledge. The small transaction size relative to Glenbrook's existing position further suggests tactical rebalancing rather than a bold bullish statement.

10% owner Glenbrook Capital buys 171,034 shares across 3 trades (blended $1.93) amid -71.2% stock decline from 52-week high

Glenbrook Capital Management, holding 10% of SenesTech, purchased 171,034 shares totaling $330,181.63 in three transactions between March 13–17, 2026, at an average price of $1.93, increasing holdings by 23.8% to 890,635 shares. The purchases occur while the stock trades at $1.77, down 71.2% from its 52-week high of $6.15 and down 11.5% over the prior 30 days. SenesTech's fundamentals show an unprofitable business (net income of $-1,298,000.00 for its most recent full fiscal year) with minimal quarterly revenue of $690,000.00, though annual revenue growth stands at 19.6%. The insider's same-ticker history shows 5 prior buys at SNES in February 2026, with measurable outcomes of +1.5% and +11.6% at the 30-day mark for two earlier trades, and no measurable 90-day outcomes yet; the cross-ticker track record shows 10 prior buys averaging +13.5% at 30 days. This accumulation by a significant shareholder during a period of substantial price weakness and financial losses warrants tracking of whether near-term price pressure has stabilized or reversed.

10% owner Glenbrook Capital purchases 85,901 shares across 3 transactions (Feb 17–19) for $200,634.84 at blended avg $2.34

Glenbrook Capital Management, holding 704.2K shares post-transaction (a 13.9% increase in holdings), executed 3 separate purchases totaling 85,901 shares for $200,634.84 between February 17–19, 2026 at prices ranging from $2.29 to $2.40. This follows 5 prior buys at SenesTech in early February, indicating sustained accumulation by a 10% shareholder. The current stock price of $2.40 sits -61.0% from its 52-week high of $6.15, while the company reported revenue of $690,000.00 in the latest quarter against net income of $-1,298,000.00, reflecting material unprofitability. The repeated purchasing pattern in a depressed price environment suggests the insider is committing capital despite near-term losses, though the outcome of these early-February trades remains unmeasurable at the 30- and 90-day windows.

10% owner GLENBROOK CAPITAL MANAGEMENT bought 31,346 shares at blended avg $1.81 across 3 trades, raising stake to 633,700 shares

GLENBROOK CAPITAL MANAGEMENT, a 10% shareholder, executed 3 separate purchases totaling 31,346 shares for $56,667.47 (blended average $1.81) on February 11–13, 2026, increasing holdings by 5.2% to 633,700 shares. This accumulation occurred within the context of severe near-term weakness: the stock is -67.5% from its 52-week high, down -29.6% over 90 days, and currently trades at $2.00. The underlying business shows structural stress—the company reported $690,000 quarterly revenue against a $-1,298,000 net loss and remains unprofitable on a full-year basis, despite +55.7% annual revenue growth. The four prior purchases at this ticker (all within the past two weeks, on 2026-01-30, 2026-02-02, 2026-02-04, and 2026-02-05) reveal a pattern of consistent accumulation into a sustained decline, with no outcomes yet measurable at the 90-day mark to assess whether the timing of these purchases proves prescient.

10% owner Glenbrook Capital bought 8,569 shares in 2 transactions at $1.81–$1.82 as stock trades -69.6% from 52-week high amid unprofitability.

Glenbrook Capital Management, a 10% shareholder, made 2 separate purchases totaling 8,569 shares for $15,479.54 at a blended average price of $1.81 on 2026-02-04 and 2026-02-05. The stock is currently at $1.87, down 69.6% from its 52-week high of $6.15 and down 44.8% over the past 90 days, placing the company in severe distress. SenesTech's fundamentals are weak: it reported net income of $-1.3M on quarterly revenue of $690.0K and remains unprofitable on a full-year basis, despite 55.7% annual revenue growth. The insider's prior trades at this ticker (2 recent buys on 2026-02-02 and 2026-01-30) lack measurable 90-day outcomes, providing no historical basis to assess timing patterns. This purchase adds 8,569 shares to a 593.8K base, increasing holdings by 1.4%, but against a backdrop of fundamental weakness, significant price deterioration, and no demonstrated track record of well-timed buying at this specific ticker.